We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Sandoz, UTC Settle Generic Remodulin Patent Suit

Law360, New York (September 30, 2015, 8:48 PM EDT) -- United Therapeutics Corp. has given Sandoz Inc. a non-exclusive license to manufacture and sell a generic version of its hypertension drug Remodulin, ending more than three years of patent litigation, UTC announced Wednesday.

The settlement allows Sandoz to make and sell its version of Remodulin starting on June 26, 2018, but that may be moved up under circumstances that UTC didn’t disclose Wednesday. The agreement is limited only to the specific version of the drug Sandoz had described in the abbreviated new drug application which sparked...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.